Start Date
September 30, 2006
Primary Completion Date
June 30, 2009
Study Completion Date
June 30, 2009
GM-CT-01
GM-CT-01 at 280 mg/m2 given IV for 4 consecutive days in 28 days cycle until disease progression
5-Fluorouracil
5-FU given IV by infusion for 30, at 600 mg/m2 in combination with GM-CT-01 for 4 consecutive days in 28 days cycle until disease progression
University of Michigan, Comprehensive Cancer Center, Ann Arbor
Boston Medical Center, Boston
Barrett Cancer Center, Cincinnati
Lead Sponsor
Galectin Therapeutics Inc.
INDUSTRY